Navigation Links
Depomed Announces Filing Of Shelf Registration To Replace Existing Shelf
Date:5/29/2012

MENLO PARK, Calif., May 29, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) announced that it has filed a "shelf" registration statement with the Securities and Exchange Commission. This will replace the Company's previously filed shelf registration statement, which will expire in June 2012 and includes the registration for the sale of common stock, preferred stock or debt securities.

The Company currently has no plan to issue any securities under the registration statement, and the terms of any future offering pursuant to the registration statement would be established at the time of the offering.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy these securities be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any such state.

About Depomed

Depomed, Inc. is a specialty pharmaceutical company with two approved and marketed products. Gralise ® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, www.depomed.com.

CONTACT: August J. Moretti

Depomed, Inc.

650-462-5900

amoretti@depomed.com


'/>"/>
SOURCE Depomed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Depomed To Present At Jefferies 2012 Global Health Care Conference
2. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
3. New 60,000 Square Foot Lease at the Pacific Research Center Signed by Biomed Realty and Depomed
4. Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex®
5. Endo Announces Resolution of Patent Litigation with Watson Pharmaceuticals Related to Lidoderm®
6. Horizon Pharma Announces Issuance of U.S. Patent Covering RAYOS (delayed-release prednisone)
7. Watson Announces Lidoderm® Patent Challenge Settlement
8. Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. Acacia Pharma Announces Excellent Phase II Results for APD421 in Post-Operative Nausea & Vomiting (PONV)
10. Mylan Announces Settlement Agreement in Patent Infringement Litigation Relating to Sunovions Brovana® Product
11. Uroplasty Announces Product Development and New Clinical Trial Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Consumers have taken ... regulators/payers have placed more emphasis on patient outcomes. ... support programs in the pharmaceutical industry have evolved ... Consequently, pharmaceutical companies are focusing on becoming more ... providing products and services that improve health. ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
Breaking Medicine News(10 mins):